From the data published in the above studies (as shown in Table 2), it is clear that the combination of ADO inhibitors and PD-1/PD-L1 inhibitors has significant potential to improve the prognosis of NSCLC, with obleclumab, a CD73 monoclonal antibody, being the most promising. Here, ADO is linked to non-small cell lung carcinoma.